(13) Other operating income
Accounting and measurement policies
Other operating income
Other operating income comprises all income that cannot be allocated to net sales or finance income on account of its character.
Income from upfront payments, milestone payments and royalties
Income from upfront payments, milestone payments and royalties, comprises consideration received by the Group from contract partners that are not customers. This relates in particular to collaboration and out-licensing agreements in the Healthcare business sector (see Note (7) “Collaboration and licensing agreements”).
Income from the revaluation of contingent considerations
The accounting treatment of contingent consideration agreed at the sale of a business as defined in IFRS 3 is shown in Note (36) “Other financial assets”.
Other operating income was broken down as follows:
€ million |
|
2022 |
|
2021 |
|---|---|---|---|---|
Income from upfront payments, milestone payments and royalties |
|
105 |
|
304 |
Realized gains from currency translation |
|
71 |
|
6 |
Income from the disposal of businesses and assets |
|
63 |
|
67 |
Income from the revaluation of contingent considerations |
|
45 |
|
7 |
Income from fair value measurement of assets |
|
38 |
|
3 |
Income from the reversal of provisions for litigation |
|
24 |
|
27 |
Income from miscellaneous services |
|
7 |
|
5 |
Reversal of impairment losses on non-financial assets |
|
– |
|
14 |
Remaining other operating income |
|
132 |
|
96 |
Other operating income |
|
486 |
|
528 |
License income primarily resulted from interferon beta products (Biogen Inc., United States) in the amount of € 55 million (2021: € 60 million) and the antidepressant Viibryd® (AbbVie Inc., United States) in the amount of € 27 million (2021: € 50 million). The year-on-year decrease in upfront payments, milestone payments, and royalties was due to the termination of the collaboration agreement with GlaxoSmithKline plc, United Kingdom (2021: € 123 million). The prior-year figure also included milestone payments of € 50 million from Pfizer Inc., United States, for approvals of Bavencio®. For further explanations see Note (7) “Collaboration and licensing agreements”.
For information on income from the reversal of provisions for litigation, see Note (27) “Other provisions”.